Minimizing immunosuppression in islet xenotransplantation

Immunotherapy

Volumn 6, Issue 4, 2014, Pages 419-430

  Shin, Jun Seop ^a   Kim, Jung Sik ^a   Kim, Jong Min ^a   Jang, Jae Yool ^a   Kim, Yong Hee ^a,b   Kim, Hyun Je ^a   Park, Chung Gyu ^a,c  

^a Seoul National University   (South Korea)

^b Kyungpook National University   (South Korea)

^c Seoul National University Hospital   (South Korea)

Author keywords

immunosuppression; islet transplantation; minimization; pig islet; Type 1 diabetes

Indexed keywords

ABATACEPT; ALEMTUZUMAB; BASILIXIMAB; BELATACEPT; BORTEZOMIB; CD40 LIGAND MONOCLONAL ANTIBODY; DACLIZUMAB; ETANERCEPT; FINGOLIMOD; LEFLUNOMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADAPTIVE IMMUNITY; ARTICLE; CHRONIC GRAFT REJECTION; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORGAN DONOR; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; SWINE; ZOONOSIS; ANIMAL; DIABETES MELLITUS, TYPE 1; HAPLORHINI; PROCEDURES; XENOGRAFT;

ANIMALS; DIABETES MELLITUS, TYPE 1; GRAFT REJECTION; HAPLORHINI; HETEROGRAFTS; HUMANS; IMMUNOSUPPRESSION; ISLETS OF LANGERHANS TRANSPLANTATION; SWINE; TRANSPLANTATION, HETEROLOGOUS;

EID: 84900505348     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.14     Document Type: Article

References (81)

1. Shapiro AM, Lakey JR, Ryan EA et al. Islet transplantation in seven patients with Type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 343(4), 230-238 (2000). (Pubitemid 30490390)
2. Ryan EA, Paty BW, Senior PA et al. Five-year followup after clinical islet transplantation. Diabetes 54(7), 2060-2069 (2005). (Pubitemid 40911269)
3. The EMMES Corporation. 6th Collaborative Islet Transplant Registry (CITR) Annual Report. CITR Coordinating Center. http://spitfire.emmes.com/study/isl/ reports/CITR%20 6th%20Annual%20Data%20Report%20120109.pdf
4. US FDA Center for Biologics Evaluation and Research. Guidance for industry. Considerations for allogeneic islet cell products. www.fda.gov/downloads/BiologicsBloodVaccines/ GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/ UCM182441.pdf
5. Mandel TE. Fetal islet xenotransplantation in rodents and primates. J. Mol. Med. 77(1), 155-160 (1999). (Pubitemid 29146208)
6. Marigliano M, Bertera S, Grupillo M, Trucco M, Bottino R. Pig-to-nonhuman primates pancreatic islet xenotransplantation: an overview. Curr. Diab. Rep. 11(5), 402-412 (2011).
7. Rijkelijkhuizen JK, Haanstra KG, Wubben J et al. T-cellspecific immunosuppression results in more than 53 days survival of porcine islets of langerhans in the monkey. Transplantation 76(9), 1359-1368 (2003). (Pubitemid 37430724)
8. Komoda H, Miyagawa S, Omori T et al. Survival of adult islet grafts from transgenic pigs with N-acetylglucosaminyltransferase-III (GnT-III) in cynomolgus monkeys. Xenotransplantation 12(3), 209-216 (2005). (Pubitemid 40524981)
9. Van Der Windt DJ, Bottino R, Casu A, Campanile N, Cooper DK. Rapid loss of intraportally transplanted islets: an overview of pathophysiology and preventive strategies. Xenotransplantation 14(4), 288-297 (2007). (Pubitemid 47174365)
10. Goto M, Groth CG, Nilsson B, Korsgren O. Intraportal pig islet xenotransplantation into athymic mice as an in vivo model for the study of the instant blood-mediated inflammatory reaction. Xenotransplantation 11(2), 195-202 (2004). (Pubitemid 38282270)
11. Goto M, Tjernberg J, Dufrane D et al. Dissecting the instant blood-mediated inflammatory reaction in islet xenotransplantation. Xenotransplantation 15(4), 225-234 (2008).
12. Friedman T, Smith RN, Colvin RB, Iacomini J. A critical role for human CD4+ T-cells in rejection of porcine islet cell xenografts. Diabetes 48(12), 2340-2348 (1999). (Pubitemid 30395425)
13. Kirchhof N, Shibata S, Wijkstrom M et al. Reversal of diabetes in non-immunosuppressed rhesus macaques by intraportal porcine islet xenografts precedes acute cellular rejection. Xenotransplantation 11(5), 396-407 (2004). (Pubitemid 39128209)
14. Cardona K, Korbutt GS, Milas Z et al. Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways. Nature Med. 12(3), 304-306 (2006). (Pubitemid 43355077)
15. Hering BJ, Wijkstrom M, Graham ML et al. Prolonged diabetes reversal after intraportal xenotransplantation of wildtype porcine islets in immunosuppressed nonhuman primates. Nature Med. 12(3), 301-303 (2006). (Pubitemid 43355076)
16. Cardona K, Milas Z, Strobert E et al. Engraftment of adult porcine islet xenografts in diabetic nonhuman primates through targeting of costimulation pathways. Am. J. Transplant. 7(10), 2260-2268 (2007). (Pubitemid 47347856)
17. Van Der Windt DJ, Bottino R, Casu A et al. Long-term controlled normoglycemia in diabetic non-human primates after transplantation with hCD46 transgenic porcine islets. Am. J. Transplant. 9(12), 2716-2726 (2009).
18. Jung KC, Park CG, Jeon YK et al. In situ induction of dendritic cell-based T cell tolerance in humanized mice and nonhuman primates. J. Exper. Med. 208(12), 2477-2488 (2011).
19. Benda B, Ljunggren HG, Peach R, Sandberg JO, Korsgren O. Co-stimulatory molecules in islet xenotransplantation: CTLA4Ig treatment in CD40 ligand-deficient mice. Cell Transplant. 11(7), 715-720 (2002). (Pubitemid 36026449)
20. Korsgren O, Nilsson B, Berne C et al. Current status of clinical islet transplantation. Transplantation 79(10), 1289-1293 (2005). (Pubitemid 40734785)
21. Bennet W, Groth CG, Larsson R, Nilsson B, Korsgren O. Isolated human islets trigger an instant blood mediated inflammatory reaction: implications for intraportal islet transplantation as a treatment for patients with Type 1 diabetes. Upsala J. Med. Sci. 105(2), 125-133 (2000).
22. Robson SC, Cooper DK, D'apice AJ. Disordered regulation of coagulation and platelet activation in xenotransplantation. Xenotransplantation 7(3), 166-176 (2000).
23. Levi M, Van Der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. Circulation 109(22), 2698-2704 (2004). (Pubitemid 38737913)
24. Ma X, Ye B, Gao F et al. Tissue factor knockdown in porcine islets: an effective approach to suppressing the instant bloodmediated inflammatory reaction. Cell Transplant. 21(1), 61-71 (2012).
25. Ozmen L, Ekdahl KN, Elgue G, Larsson R, Korsgren O, Nilsson B. Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation. Diabetes 51(6), 1779-1784 (2002). (Pubitemid 34564290)
26. Brissova M, Shostak A, Shiota M et al. Pancreatic islet production of vascular endothelial growth factor-a is essential for islet vascularization, revascularization, and function. Diabetes 55(11), 2974-2985 (2006). (Pubitemid 44923633)
27. Van Der Windt DJ, Marigliano M, He J et al. Early islet damage after direct exposure of pig islets to blood: has humoral immunity been underestimated? Cell Transplant. 21(8), 1791-1802 (2012).
28. Kang HJ, Ha JM, Lee JI. Inhibitor of alternative complement pathway protects porcine islet in contact with human blood from an attack by complement activation. Presented at: 24th International Congress of the Transplantation Society. Berlin, Germany, 15-19 July 2012.
29. Moberg L, Korsgren O, Nilsson B. Neutrophilic granulocytes are the predominant cell type infiltrating pancreatic islets in contact with ABO-compatible blood. Clin. Exp. Immunol. 142(1), 125-131 (2005). (Pubitemid 41361015)
30. Contreras JL, Eckstein C, Smyth CA et al. Activated protein C preserves functional islet mass after intraportal transplantation: a novel link between endothelial cell activation, thrombosis, inflammation, and islet cell death. Diabetes 53(11), 2804-2814 (2004). (Pubitemid 39425905)
31. Szaba FM, Smiley ST. Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood 99(3), 1053-1059 (2002). (Pubitemid 34525570)
32. Biancone L, Cantaluppi V, Romanazzi GM et al. Plateletactivating factor synthesis and response on pancreatic islet endothelial cells: relevance for islet transplantation. Transplantation 81(4), 511-518 (2006).
33. Vanichakarn P, Blair P, Wu C, Freedman JE, Chakrabarti S. Neutrophil CD40 enhances platelet-mediated inflammation. Thromb. Res. 122(3), 346-358 (2008).
34. Bennet W, Sundberg B, Groth CG et al. Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes 48(10), 1907-1914 (1999). (Pubitemid 29458351)
35. Pileggi A, Molano RD, Berney T et al. Heme oxygenase-1 induction in islet cells results in protection from apoptosis and improved in vivo function after transplantation. Diabetes 50(9), 1983-1991 (2001). (Pubitemid 33643664)
36. Zhai C, Yu L, Zhu H, Tian M, Xiaogang Z, Bo W. Porcine CTLA4-Ig prolong islet xenografts in rats by downregulating the direct pathway of T-cell activation. Xenotransplantation 18(1), 40-45 (2011).
37. Thompson P, Badell IR, Lowe M et al. Alternative immunomodulatory strategies for xenotransplantation: CD40/154 pathway-sparing regimens promote xenograft survival. Am. J. Transplant. 12(7), 1765-1775 (2012).
38. Liu C, Noorchashm H, Sutter JA et al. B lymphocytedirected immunotherapy promotes long-term islet allograft survival in nonhuman primates. Nature Med. 13(11), 1295-1298 (2007). (Pubitemid 350073600)
39. Li S, Yan Y, Lin Y et al. Rapidly induced, T-cell independent xenoantibody production is mediated by marginal zone B cells and requires help from NK cells. Blood 110(12), 3926-3935 (2007). (Pubitemid 350248448)
40. Hecht G, Eventov-Friedman S, Rosen C et al. Embryonic pig pancreatic tissue for the treatment of diabetes in a nonhuman primate model. Proc. Natl Acad. Sci. USA 106(21), 8659-8664 (2009).
41. Thompson P, Cardona K, Russell M et al. CD40-specific costimulation blockade enhances neonatal porcine islet survival in nonhuman primates. Am. J. Transplant. 11(5), 947-957 (2011).
42. Thompson P, Badell IR, Lowe M et al. Islet xenotransplantation using gal-deficient neonatal donors improves engraftment and function. Am. J. Transplant. 11(12), 2593-2602 (2011).
43. Halloran PF. Immunosuppressive drugs for kidney transplantation. N. Engl. J. Med. 351(26), 2715-2729 (2004). (Pubitemid 39665325)
44. Budde K, Schutz M, Glander P et al. FTY720 (fingolimod) in renal transplantation. Clin. Transplant. 20(Suppl. 17), 17-24 (2006). (Pubitemid 44697897)
45. Manna SK, Mukhopadhyay A, Aggarwal BB. Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J. Immunol. 165(10), 5962-5969 (2000).
46. Hancock WW, Miyatake T, Koyamada N et al. Effects of leflunomide and deoxyspergualin in the guinea pigrat cardiac model of delayed xenograft rejection: suppression of B cell and C-C chemokine responses but not induction of macrophage lectin. Transplantation 64(5), 696-704 (1997). (Pubitemid 27407095)
47. Ekser B, Ezzelarab M, Hara H et al. Clinical xenotransplantation: the next medical revolution? Lancet 379(9816), 672-683 (2012).
48. Sun Y, Ma X, Zhou D, Vacek I, Sun AM. Normalization of diabetes in spontaneously diabetic cynomologus monkeys by xenografts of microencapsulated porcine islets without immunosuppression. J. Clin. Invest. 98(6), 1417-1422 (1996). (Pubitemid 26322067)
49. Dufrane D, Goebbels RM, Gianello P. Alginate macroencapsulation of pig islets allows correction of streptozotocin-induced diabetes in primates up to 6 months without immunosuppression. Transplantation 90(10), 1054-1062 (2010).
50. Dufrane D, Gianello P. Macro-or microencapsulation of pig islets to cure Type 1 diabetes. World. J. Gastroenterol. 18(47), 6885-6893 (2012).
51. Sakata N, Sumi S, Yoshimatsu G, Goto M, Egawa S, Unno M. Encapsulated islets transplantation: Past, present and future. World. J. Gastrointest. Pathophysiol. 3(1), 19-26 (2012).
52. Hering BJ, Kandaswamy R, Ansite JD et al. Single-donor, marginal-dose islet transplantation in patients with Type 1 diabetes. JAMA 293(7), 830-835 (2005). (Pubitemid 40250366)
53. Takita M, Matsumoto S, Shimoda M et al. Safety and tolerability of the T-cell depletion protocol coupled with anakinra and etanercept for clinical islet cell transplantation. Clin. Transplant. 26(5), E471-E484 (2012).
54. Rickels MR, Liu C, Shlansky-Goldberg RD et al. Improvement in beta-cell secretory capacity after human islet transplantation according to the CIT07 protocol. Diabetes 62(8), 2890-2897 (2013).
55. Shapiro AM. Strategies toward single-donor islets of Langerhans transplantation. Curr. Opin. Organ Transplant. 16(6), 627-631 (2011).
56. Nilsson B, Ekdahl KN, Korsgren O. Control of instant blood-mediated inflammatory reaction to improve islets of Langerhans engraftment. Curr. Opin. Organ Transplant. 16(6), 620-626 (2011).
57. Citro A, Cantarelli E, Piemonti L. Anti-inflammatory strategies to enhance islet engraftment and survival. Curr. Diabetes Rep.13(5), 733-744(2013).
58. Goto M, Johansson H, Maeda A, Elgue G, Korsgren O, Nilsson B. Low molecular weight dextran sulfate prevents the instant blood-mediated inflammatory reaction induced by adult porcine islets. Transplantation 77(5), 741-747 (2004). (Pubitemid 38366981)
59. Goto M, Johansson H, Maeda A, Elgue G, Korsgren O, Nilsson B. Low-molecular weight dextran sulfate abrogates the instant blood-mediated inflammatory reaction induced by adult porcine islets both in vitro and in vivo. Transplant. Proc. 36(4), 1186-1187 (2004). (Pubitemid 38766317)
60. Johansson H, Goto M, Dufrane D et al. Low molecular weight dextran sulfate: a strong candidate drug to block IBMIR in clinical islet transplantation. Am. J. Transplant. 6(2), 305-312 (2006). (Pubitemid 43382165)
61. Armstrong PC, Peter K. GPIIb/IIIa inhibitors: from bench to bedside and back to bench again. Thromb. Haemost. 107(5), 808-814 (2012).
62. Berman DM, Cabrera O, Kenyon NM et al. Interference with tissue factor prolongs intrahepatic islet allograft survival in a nonhuman primate marginal mass model. Transplantation 84(3), 308-315 (2007). (Pubitemid 47258317)
63. Rood PP, Bottino R, Balamurugan AN et al. Reduction of early graft loss after intraportal porcine islet transplantation in monkeys. Transplantation 83(2), 202-210 (2007). (Pubitemid 46185211)
64. Tokodai K, Goto M, Inagaki A et al. C5a-inhibitory peptide combined with gabexate mesilate prevents the instant blood-mediated inflammatory reaction in a rat model of islet transplantation. Transplant. Proc. 42(6), 2102-2103 (2010).
65. Bennet W, Sundberg B, Lundgren T et al. Damage to porcine islets of Langerhans after exposure to human blood in vitro, or after intraportal transplantation to cynomologus monkeys: protective effects of sCR1 and heparin. Transplantation 69(5), 711-719 (2000). (Pubitemid 30174086)
66. Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohn's disease. World. J. Gastroenterol. 18(35), 4823-4854 (2012).
67. Atzeni F, Benucci M, Salli S, Bongiovanni S, Boccassini L, Sarzi-Puttini P. Different effects of biological drugs in rheumatoid arthritis. Autoimmun. Rev. 12(5), 575-579 (2013).
68. Gala-Lopez B, Pepper AR, Shapiro AM. Biologic agents in islet transplantation. Curr. Diab. Rep. (13(5), 713-722 (2013).
69. Citro A, Cantarelli E, Maffi P et al. CXCR1/2 inhibition enhances pancreatic islet survival after transplantation. J. Clin. Invest. 122(10), 3647-3651 (2012).
70. Mulder A, Heidt S, Vergunst M, Roelen DL, Claas FH. Proteasome inhibition profoundly affects activated human B cells. Transplantation 95(11), 1331-1337 (2013).
71. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nature Med. 6(2), 114 (2000). (Pubitemid 30082329)
72. Imai A, Suzuki T, Sugitani A et al. A novel fully human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys. Transplantation 84(8), 1020-1028 (2007). (Pubitemid 350287383)
73. Oura T, Yamashita K, Suzuki T et al. Long-term hepatic allograft acceptance based on CD40 blockade by ASKP1240 in nonhuman primates. Am. J. Transplant. 12(7), 1740-1754 (2012).
74. Watanabe M, Yamashita K, Suzuki T et al. ASKP1240, a fully human anti-CD40 monoclonal antibody, prolongs pancreatic islet allograft survival in nonhuman primates. Am. J. Transplant. 13(8), 1976-1988 (2013).
75. Goldwater R, Keirns J, Blahunka P et al. A Phase 1, randomized ascending single-dose study of antagonist anti-human CD40 ASKP1240 in healthy subjects. Am. J. Transplant. 13(4), 1040-1046 (2013).
76. Wakefield I, Peters C, Burkly L. CDP7657, a monovalent Fab PEG anti-CD40L antibody, inhibits immune responses in both HuSCID mice and non-human primates. Arthritis Rheum. 62(Suppl. 10), 1245 (2010).
77. Barton FB, Rickels MR, Alejandro R et al. Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care 35(7), 1436-1445 (2012).
78. Kwun J, Bulut P, Kim E et al. The role of B cells in solid organ transplantation. Semin. Immunol. 24(2), 96-108 (2012).
79. Hering BJ, Cooper DK, Cozzi E et al. The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in Type 1 diabetes-executive summary. Xenotransplantation 16(4), 196-202 (2009).
80. Groth CG, Korsgren O, Tibell A et al. Transplantation of porcine fetal pancreas to diabetic patients. Lancet 344(8934), 1402-1404 (1994). (Pubitemid 24365315)
81. Wang W, Mo Z, Ye B, Hu P, Liu S, Yi S. A clinical trial of xenotransplantation of neonatal pig islets for diabetic patients. Zhong Nan Da Xue Xue Bao Yi Xue Ban 36(12), 1134-1140 (2011).